ÂÜÀòÂÒÂ×

Luke Devey has a diverse work experience spanning over several years. Luke is currently the Chief Medical Officer at Quell Therapeutics, starting in November 2022. Prior to this role, Luke held the position of Visiting Professor of Immunology at the University of Oxford from May 2020. Luke also worked as the Vice President and Head of Translational Science, Immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson from January 2020 until November 2022. Before that, they served as the Executive Director and Head of Early Discovery Biology, I&I TCoE at Celgene from March 2018 to January 2020. Luke has also had significant experience at GlaxoSmithKline, where they worked as the Senior Director of Translational Medicine from June 2013 to March 2018. In addition, they held positions at The University of Edinburgh as a Health Foundation/ Academy of Medical Sciences Clinician Scientist Fellow from February 2009 to May 2013, and at the NHS as a Specialist Registrar in Surgery from October 2008 to January 2013. Luke started their career as an MRC Clinical Research Training Fellow, first at the University of Birmingham/Medical Research Council from December 2005 to March 2007, and then at the University of Edinburgh from February 2004 to December 2005. Luke also worked as a Senior House Officer at the South East Scotland Basic Surgical Training Scheme from August 1999 to February 2004.

Luke Devey completed their Bachelor of Medicine and Bachelor of Surgery (BMBCh) degree at the University of Oxford between 1992 and 1998. In 1995, they also obtained a Master of Arts (MA) degree in Physiological Sciences from the same university. Luke further pursued their education and earned a Doctor of Philosophy (PhD) degree in Medicine from the University of Birmingham from 2005 to 2007. In 2001, Luke enrolled at the Royal College of Surgeons of Edinburgh to pursue a degree in Surgery, but the end year is unspecified.